Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients: Pilot Study Phase I/II
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms Nivo-TIL
- 31 Aug 2018 Biomarkers information updated
- 19 Feb 2018 Planned End Date changed from 15 Feb 2021 to 12 Mar 2021.
- 19 Feb 2018 Planned primary completion date changed from 15 Feb 2021 to 12 Mar 2021.